Press Releases

Date Title and Summary Additional Formats
Toggle Summary "THINK FUNGUS" - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
The first Fungal Disease Awareness Week is designed to increase awareness about fungal diseases, which can cause severe illness but frequently go undiagnosed
View HTML
Toggle Summary Abide Therapeutics and SCYNEXIS Collaborate in Finding Novel Anti-Viral and Anti-Parasitic Agents View HTML
Toggle Summary Companies Collaborate to Provide Innovative Synthetic Process for Cancer Treatment Drug View HTML
Toggle Summary DNDi Launches Phase I In-Human Clinical Trial for Promising Oral Drug for Sleeping Sickness View HTML
Toggle Summary Dr. Dennis Schmatz Joins SCYNEXIS as Strategic Advisor View HTML
Toggle Summary Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS' Lead Anti-infective Candidate SCY-078
Presentations support SCY-078's potential as a novel treatment for  Candida infections including multidrug-resistant strains Favorable safety profile of SCY-078 supported by clinical studies presented Conference call to review ECCMID SCY-078 data to be held April 25 at 4:05 p.m.
View HTML
Toggle Summary Eight Presentations at ASM Microbe 2017 Further Highlight the Strong Antifungal Effect and Promising Safety Profile of Lead Anti-Infective Candidate SCY-078
Potent and broad activity of SCY-078 shown against more than 300 clinical Candida isolates    Multiple studies confirm high compatibility of SCY-078 with other antifungals and favorable safety profile   JERSEY CITY, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
View HTML
Toggle Summary Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS' Lead Agent to Combat Serious and Life-threatening Fungal Infections
JERSEY CITY, N.J., May 24, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced eight poster presentations at ASM Microbe 2017 , June 1 through 5 in
View HTML
Toggle Summary First Candidate from SCYNEXIS’ Novel Cyclophilin Inhibitor Platform, SCY 635, Establishes Proof of Concept in HCV-Infected Adults View HTML
Toggle Summary Innovative Partnership Advances Novel Drug Candidate to Combat Sleeping Sickness
PLoS Journal article highlights initial research success of a boron-based compound, ready to enter into clinical development, resulting from collaboration between two U.S. biotechs and DNDi
View HTML